Intercalation-Driven Formation of siRNA Nanogels for Cancer Therapy
RNA interference (RNAi) is a powerful approach in the treatment of various diseases including cancers. The clinical translation of small interfering RNA (siRNA)-based therapy requires safe and efficient delivery vehicles. Here, we report a siRNA nanogels (NG)-based delivery vehicle, which is driven directly by the intercalation between nucleic acid bis-intercalator and siRNA molecules. The intercalation-based siRNA NG exhibits good physiological stability and can enter cells efficiently via different endocytosis pathways. Furthermore, the siRNA NG can not only silence the target genes in vitro but also significantly inhibit the tumor growth in vivo. Therefore, this study provides an intercalation-based strategy for the development of a siRNA delivery platform for cancer therapy. To the best of our knowledge, this is the first report of the intercalation-driven siRNA NG.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
Nano letters - 21(2021), 22 vom: 24. Nov., Seite 9706-9714 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Huang, Xiangang [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer therapy |
|---|
| Anmerkungen: |
Date Completed 09.03.2022 Date Revised 09.03.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1021/acs.nanolett.1c03539 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM332617939 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM332617939 | ||
| 003 | DE-627 | ||
| 005 | 20231225215933.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1021/acs.nanolett.1c03539 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1108.xml |
| 035 | |a (DE-627)NLM332617939 | ||
| 035 | |a (NLM)34723546 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Huang, Xiangang |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Intercalation-Driven Formation of siRNA Nanogels for Cancer Therapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 09.03.2022 | ||
| 500 | |a Date Revised 09.03.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a RNA interference (RNAi) is a powerful approach in the treatment of various diseases including cancers. The clinical translation of small interfering RNA (siRNA)-based therapy requires safe and efficient delivery vehicles. Here, we report a siRNA nanogels (NG)-based delivery vehicle, which is driven directly by the intercalation between nucleic acid bis-intercalator and siRNA molecules. The intercalation-based siRNA NG exhibits good physiological stability and can enter cells efficiently via different endocytosis pathways. Furthermore, the siRNA NG can not only silence the target genes in vitro but also significantly inhibit the tumor growth in vivo. Therefore, this study provides an intercalation-based strategy for the development of a siRNA delivery platform for cancer therapy. To the best of our knowledge, this is the first report of the intercalation-driven siRNA NG | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a RNAi | |
| 650 | 4 | |a cancer therapy | |
| 650 | 4 | |a intercalation | |
| 650 | 4 | |a nanogels | |
| 650 | 4 | |a siRNA delivery | |
| 650 | 7 | |a Nanogels |2 NLM | |
| 650 | 7 | |a RNA, Small Interfering |2 NLM | |
| 700 | 1 | |a Wu, Gongwei |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Chuang |e verfasserin |4 aut | |
| 700 | 1 | |a Hua, Xianwu |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Zhongmin |e verfasserin |4 aut | |
| 700 | 1 | |a Xiao, Yufen |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Wei |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Jun |e verfasserin |4 aut | |
| 700 | 1 | |a Kong, Na |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Peng |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Jinjun |e verfasserin |4 aut | |
| 700 | 1 | |a Tao, Wei |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Nano letters |d 2001 |g 21(2021), 22 vom: 24. Nov., Seite 9706-9714 |w (DE-627)NLM154096849 |x 1530-6992 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:22 |g day:24 |g month:11 |g pages:9706-9714 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1021/acs.nanolett.1c03539 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 22 |b 24 |c 11 |h 9706-9714 | ||